An AMH result is often described as an “egg count”, but that shorthand can create more certainty than the test provides. Anti-Müllerian hormone reflects activity in small developing follicles in the ovaries. It helps estimate ovarian reserve—the remaining pool from which eggs may develop—but it cannot count every egg or tell you the quality of those eggs.
AMH is particularly useful in fertility care when planning ovarian stimulation and anticipating how the ovaries might respond. It can also add context when reduced ovarian reserve or polycystic ovary syndrome is being considered. It is much less useful as a stand-alone forecast of whether you will become pregnant naturally in a particular month.
Age remains central. Two people with the same AMH but different ages do not have identical fertility prospects, because egg quality and chromosome risk change with age in ways AMH does not measure. Your menstrual history, ultrasound findings, partner factors and wider health also matter.
What this test measures
AMH is produced by granulosa cells around small follicles. A higher concentration generally corresponds to a larger pool of these follicles, while a lower concentration generally corresponds to a smaller pool. Unlike FSH and oestradiol, AMH changes less across the menstrual cycle, so it can often be measured on any cycle day.
Laboratories may use different assays and units, commonly pmol/L or ng/mL. Reference information should therefore come from the reporting laboratory. Age-specific context is more helpful than labelling one value universally “good” or “bad”.
The test does not assess whether the fallopian tubes are open, whether ovulation happens reliably, sperm factors, the uterine environment or genetic quality of eggs. It also does not establish polycystic ovary syndrome by itself; symptoms, cycle history and sometimes ultrasound or other hormone results are needed.
When testing may be useful
Testing may be useful before assisted fertility treatment, after discussion of egg freezing, when periods have become unexpectedly irregular or absent, or when surgery, chemotherapy or another factor may affect ovarian reserve. It can help a fertility specialist tailor medication and discuss expected egg yield.
If you are trying to become pregnant, do not use AMH alone to decide whether to wait or seek help. NHS advice generally supports seeing a GP after one year of trying, or sooner if you are aged 36 or over, know you may have fertility problems or have irregular cycles.
Hormonal contraception, pregnancy and some ovarian conditions can affect interpretation. Tell the provider about contraception, previous ovarian surgery and fertility treatment. Seek clinical assessment for significant pelvic pain, very irregular bleeding or other concerning symptoms rather than treating AMH as a general pelvic-health screen.
What your results can mean
A lower AMH suggests fewer recruitable follicles compared with people of a similar age, but natural conception can still occur. It may indicate a lower response to ovarian stimulation, yet it cannot specify the number of useful eggs or the likelihood that an individual embryo will result in a birth.
A higher AMH can be seen with a larger follicle pool and is often found in people with polycystic ovaries. In fertility treatment it may signal a stronger response and a need for careful medication planning. It is not evidence that fertility will remain high indefinitely.
Small changes on repeat testing may reflect analytical and biological variation rather than a meaningful shift. Repeating AMH frequently to track an exact decline is rarely as informative as discussing age, timescale and reproductive goals with a specialist.
What to do next
Read your result with its units and laboratory guidance, then place it beside your age and reason for testing. If you are considering fertility treatment or preservation, take the report to a fertility clinic rather than using an online age chart as the sole interpretation.
Ask what the result changes. It may influence whether treatment is urgent, which stimulation dose is considered or whether ultrasound antral follicle count would add information. If it does not change a decision, more testing may not be useful.
Avoid treating a low result as proof that pregnancy is impossible or a high result as permission to delay plans. AMH is one planning tool. A clinician can combine it with menstrual history, ultrasound and the factors relevant to you and, where applicable, your partner.
See the Anti-Müllerian Hormone (AMH) Test, read what hormone panels can and cannot say about perimenopause, or explore women's health tests.
References
- University Hospitals Plymouth NHS: Anti-Müllerian hormone test
- North West London Pathology: Anti-Müllerian hormone
- NHS: Infertility
Sources: University Hospitals Plymouth NHS: Anti-Müllerian hormone test; North West London Pathology: Anti-Müllerian hormone; NHS: Infertility — see all references